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Prediabetes Is Associated With
Structural Brain Abnormalities:
The Maastricht Study
Diabetes Care 2018;41:2535–2543 | https://doi.org/10.2337/dc18-1132
OBJECTIVE
Structural brain abnormalities are key risk factors for brain diseases, such as
dementia, stroke, and depression, in type 2 diabetes. It is unknown whether
structural brain abnormalities already occur in prediabetes. Therefore, we in-
vestigated whether both prediabetes and type 2 diabetes are associated with
lacunar infarcts (LIs), white matter hyperintensities (WMHs), cerebral microbleeds
(CMBs), and brain atrophy.
RESEARCH DESIGN and METHODS
We used data from 2,228 participants (1,373 with normal glucose metabolism
[NGM], 347 with prediabetes, and 508 with type 2 diabetes (oversampled); mean
age 59.2 6 8.2 years; 48.3% women) of the Maastricht Study, a population-based
cohort study. Diabetes status was determined with an oral glucose tolerance test.
Brain imaging was performed with 3 Tesla MRI. Results were analyzed with
multivariable logistic and linear regression analyses.
RESULTS
Prediabetes and type 2 diabetes were associated with the presence of LIs (odds
ratio 1.61 [95% CI 0.98–2.63] and 1.67 [1.04–2.68], respectively; Ptrend = 0.027),
larger WMH (b 0.07 log10-transformed mL [log-mL] [95% CI 0.00–0.15] and
0.21 log-mL [0.14–0.28], respectively; Ptrend <0.001), and smaller white matter
volumes (b 24.0 mL [27.3 to 20.6] and 27.2 mL [210.4 to 24.0], respectively;
Ptrend <0.001) compared with NGM. Prediabetes was not associated with gray
matter volumes or the presence of CMBs.
CONCLUSIONS
Prediabetes is associated with structural brain abnormalities, with further de-
terioration in type 2 diabetes. These results indicate that, in middle-aged pop-
ulations, structural brain abnormalities already occur in prediabetes, which may
suggest that the treatment of early dysglycemia may contribute to the prevention
of brain diseases.
Structural brain abnormalities are thought to be an important pathway through which
type 2 diabetes causes brain diseases (1). Indeed, there is extensive evidence that
type 2 diabetes is associated with an increased risk of brain diseases, such as stroke,
dementia, and depression (1–9), and of structural brain abnormalities on MRI, such
as lacunar infarcts (LIs), white matter hyperintensities (WMHs), and brain atrophy
(10), which in turn are associated with an increased risk of stroke, dementia, and
depression (11–13).
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Whether prediabetes (defined as im-
paired fasting glucose or impaired glu-
cose tolerance [14]) is also associated
with an increased risk of structural brain
abnormalities and brain diseases is not
clear (15). However, this appears to be a
distinct possibility because structural
brain abnormalities in type 2 diabetes
are thought to be, to an important ex-
tent, of micro- and macrovascular ori-
gin (16–19) and because (extracranial)
micro- and macrovascular dysfunction has
been shown to be present not only in
type 2 diabetes but also in prediabetes
(the so-called ticking clock hypothesis)
(20–22). In contrast to this hypothesis,
the Atherosclerosis Risk in Communi-
ties Neurocognitive Study (ARIC-NCS)
recently reported no associations of
prediabetes with LIs, WMHs, cerebral
microbleeds (CMBs), or smaller brain
volumes in an elderly study population
(23). However, the development of struc-
tural brain abnormalities may start at
middle age (24), and no studies have
investigated this in a middle-aged pop-
ulation. It is important to know whether
prediabetes is associated with structural
brain abnormalities, as this would add to
the accumulating evidence that predia-
betes is not a benign state (25–27). In
addition, this would imply that predia-
betes provides a window of opportunity
for the prevention of brain diseases in
type 2 diabetes.
Therefore, we investigated whether
prediabetes and continuous measures
of hyperglycemia (glycated hemoglobin
[HbA1c] and fasting and 2-h plasma glu-
cose from an oral glucose tolerance test
[OGTT]) are associated with structural
brain abnormalities. In addition, we inves-
tigated whether any such associations
were independent of cardiovascular risk
factors, such as hypertension, as cardio-
vascular risk factors are an important
alternative explanation for any associa-
tion between (pre)diabetes and struc-
tural brain abnormalities.
RESEARCH DESIGN AND METHODS
Study Population and Design
We used data from the Maastricht Study,
an observational population-based co-
hort study. The rationale and method-
ology have previously been described
(28). In brief, the study focuses on the
etiology, pathophysiology, complica-
tions, and comorbidities of type 2 diabe-
tes and is characterized by an extensive
phenotyping approach. Eligible for par-
ticipation were all individuals aged be-
tween 40 and 75 years and living in the
southern part of the Netherlands. Par-
ticipants were recruited through mass
media campaigns, the municipal regis-
tries, and the regional Diabetes Patient
Registry via mailings. Recruitment was
stratified according to known type 2 di-
abetes status, with an oversampling of
individuals with type 2 diabetes for rea-
sons of efficiency. The present report
includes cross-sectional data from 3,451
participants, who completed the base-
line survey between November 2010
and September 2013. The examinations
of each participant were performed
within a time window of 3 months. MRI
measurements were implemented from
December 2013 onward until February
2017 and were available in 2,313 of 3,451
participants. Eleven MRI scans were
excluded owing to pathology (n = 2),
metal artifacts (n = 1), or insufficient
scan quality (n = 8). Participants with
type1diabetes orother types of diabetes
(n = 27) were excluded from the analysis.
In the remaining 2,275 participants, com-
plete data on covariates were available in
2,228 participants (Supplementary Fig.
1). The study has been approved by the
institutional medical ethics committee
(NL31329.068.10) and the Minister of
Health, Welfare and Sport of the Neth-
erlands (permit 131088-105234-PG).
All participants gave written informed
consent.
Diabetes Status
For determination of (pre)diabetes sta-
tus, all participants, except those who
used insulin, underwent a standardized
2-h 75-g OGTT after an overnight fast. For
safety reasons, participants with a fasting
glucose level .11.0 mmol/L, as deter-
mined by a fingerprick, did not undergo
the OGTT (n = 42). For these individuals,
fasting glucose level and information
about diabetes medication use were
used to determine diabetes status. Di-
abetes status was defined according
to the World Health Organization 2006
criteria as normal glucose metabolism
(NGM), prediabetes (impaired fasting
glucose [6.1–7.0 mmol/L] or impaired
glucose tolerance [2-h postdose OGTT
glucose 7.8–11.1 mmol/L]), or type 2
diabetes (fasting plasma glucose $7.1,
2-h postdose OGTT glucose .11.1, or
the use of diabetes medication) (14).
Individuals without type 1 diabetes on
diabetes medication were classified as
having type 2 diabetes (28).
Measures of Glycemia
Venous fasting and postload plasma
glucose levels were measured by the
enzymatic hexokinase method on two
automatic analyzers (the Synchron LX20
[Beckman Coulter Inc.] for samples ob-
tained between November 2010 and
April 2012 and the cobas 6000 [Roche
Diagnostics, Mannheim, Germany] for
samples obtained thereafter). HbA1c
was determined by ion-exchange high-
performance liquid chromatography
(28).
Brain MRI
Brain MRI was performed on a 3 Tesla
(3T) MRI scanner (MAGNETOM Prisma-
fit Syngo MR D13D; Siemens Healthcare,
Erlangen, Germany) by use of a 64-
element head coil for parallel imaging.
The MRI protocol consisted of a three-
dimensional T1-weighted (T1) sequence
(repetition time/echo time/inversion
time 2,300/2.98/900 ms, 1.00 mm cubic
voxel, 176 continuous slices, matrix size
of 240 3 250, and reconstructed matrix
size of 512 3 51), a T2-weighted fluid-
attenuated inversion recovery (FLAIR)
(repetition time/echo time/inversion
time 5,000/394/1,800 ms, 0.98 3 0.98
3 1.26 mm acquisition voxel and 0.493
0.49 3 1.00 mm reconstructed voxel,
176 continuous slices, acquisition matrix
size of 250 3 250, and reconstructed
matrix size of 512 3 51), and a gradi-
ent recalled echo (GRE) pulse sequence
with susceptibility-weighted imaging
(SWI). Contraindications for MRI assess-
ments were the presence of a cardiac
pacemaker or implantable cardioverter
defibrillator, neurostimulator, nonde-
tachable insulin pump, metallic vascular
clips or stents in the head, cochlear
implant, metal-containing intrauterine
device, metal splinters or shrapnel,
dentures with magnetic clip, an inside
bracket, pregnancy, epilepsy, and claus-
trophobia. The protocols for MRI acqui-
sition and analysis were in line with the
current STRIVE (STandards for ReportIng
Vascular changes on nEuroimaging) V1
imaging standards (29).
Measurements of Markers of Cerebral
Small-Vessel Disease
T2-weighted FLAIR and T1 images were
used to identify WMHs (30). WMHs
identified were summed to assess total
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WMH burden in milliliters. Periventric-
ular WMHs (pWMHs) were automatically
defined as WMHs ,3 mm and deep
cortical WMH (dWMHs) as WMHs $3
mm from the cerebrospinal fluid (CSF)
(31). This method has a small chance of
misclassification of juxtacortical WMHs,
which are relatively uncommon (32), as
pWMHs. LIs were defined as focal lesions
of $3 and ,15 mm in size with a signal
intensity similar to that of CSF on all
sequences and a hyperintense rim on T2
and FLAIR images (29). CMBs were rated
on three-dimensional T2* GRE imaging
with SWI by use of the Microbleed
Anatomical Rating Scale (33) and were
defined as focal lesions of $2 and
#10 mm in size with a hypointense signal
on T2* GRE and SWI images (29). The
number and location of LIs and CMBs
were rated manually by three neuroradi-
ologists. The intraclass correlation coeffi-
cient (95% CI) for the three raters based
on 50 randomly selected scans was 0.84
(0.74–0.91) and 0.83 (0.72–0.90) for the
presence of LIs and CMBs, respectively.
Measurements of Brain Volumes
T1 images and T2-weighted FLAIR im-
ages were analyzed by use of an ISO-
13485:2012–certified, automated method
(which included visual inspection)
(30,34). T1 images were segmented into
gray matter, white matter, and CSF
volumes (1 voxel = 1.00 mm3 = 0.001
mL) (34). Intracranial volume was calcu-
lated as the sum of gray matter, white
matter (including WMH volume), and CSF
volumes.
General Characteristics and Covariates
As previously described (28), educational
level (low, intermediate, high), smoking
status (never, current, former) and his-
tory of cardiovascular disease were as-
sessed by questionnaires. Medication
use was assessed in a medication in-
terview where generic name, dose, and
frequency were registered. We mea-
sured weight, height, BMI, waist circum-
ference, blood pressure (measured in
office and via ambulatory 24-h blood
pressure monitoring at home [WatchBP
03; Microlife AG, Widnau, Switzerland]),
serum creatinine, 24-h urinary albumin
excretion (twice), andplasma lipid profile
as previously described (28). Estimated
glomerular filtration rate (in mL/min/
1.73 m2) was calculated with the Chronic
Kidney Disease Epidemiology Collabora-
tion (CKD-EPI) equation based on both
serum creatinine and serum cystatin C
(35).
Statistical Analysis
All statistical analyses were performed
byuse of the Statistical Package for Social
Sciences (version 22.0; IBM, Chicago, IL).
General characteristics of the study pop-
ulation were presented as mean 6 SD,
as median (interquartile range), or as
percentages and were evaluated by
ANOVA (continuous variables with a nor-
mal distribution) or x2 tests (categorical
variables). We used multiple linear re-
gression analysis to investigate the as-
sociation of (pre)diabetes status, HbA1c,
fasting plasma glucose, or 2-h postload
glucose levels with WMH, white matter,
graymatter, andCSF volumes and logistic
regression analysis to investigate the
association with LIs (yes/no) and CMBs
(yes/no). For linear trend analyses, the
categorical variable glucose metabolism
status (NGM = 0, prediabetes = 1, and
type 2 diabetes = 2) was used in the
regression models. For assessment of
regression coefficients per glucose me-
tabolism group, analyses with dummy
variables for prediabetes and type 2 di-
abetes were used. Model 1 was adjusted
for age, sex, and the time between the
baseline and MRI measurement. Model
2 was additionally adjusted for BMI,
smoking status, total–to–HDL choles-
terol ratio, serum triglycerides, eGFR,
office systolic blood pressure, and edu-
cational level. For analyses of total,
dWMH, pWMH, white matter, and
gray matter volumes, additional adjust-
ment for intracranial volume was in-
cluded for model 1. Skewed variables
(WMH, dWMH, and pWMH volumes)
were log10 transformed. AP value,0.05
was considered statistically significant.
Interaction terms (e.g., prediabetes* sex,
type 2 diabetes * sex, or HbA1c * sex)
were incorporated in the regression
models to test for interaction among,
on the one hand, prediabetes, type 2
diabetes, and measures of hyperglyce-
mia and, on the other hand, age and
sex, on structural brain abnormalities. A
Pinteraction ,0.10 was considered statis-
tically significant.
RESULTS
General Characteristics of the Study
Population
Table 1 shows the general characteristics
of the study population, stratified by
(pre)diabetes status. The study popula-
tion consisted of 2,228 participants;
1,373 participants had NGM, 347 had
prediabetes, and 508 had type 2 diabe-
tes. The mean age was 59.26 8.2 years,
and 48.3% were women. Participants
with prediabetes and type 2 diabetes
were more likely to be older, less likely
to be female, more likely to have an ad-
verse cardiovascular risk profile, more
likely to be current smokers, and more
likely to have a low educational level
(Table 1). Individuals who underwent
MRI were more likely to be younger,
were less likely to have type 2 diabetes,
were less likely to be current smokers,
and were less likely to have a low edu-
cational level compared with the study
population that did not undergo MRI
(Supplementary Table 1).
Prediabetes and Structural Brain
Abnormalities
After full adjustment, prediabetes and
type 2 diabetes were significantly asso-
ciated with the presence of LIs (odds ratio
[OR] 1.61 [95% CI 0.98–2.63] and 1.67
[1.04–2.68], respectively; Ptrend = 0.027)
(Table 2) and larger volumes of WMHs
(b 0.07 log10-transformed mL [log-mL]
[95% CI 0.00–0.15] and 0.22 log-mL
[0.16–0.29], respectively; Ptrend ,0.001)
(Table 2) compared with NGM. In addi-
tion, both prediabetes and type 2 dia-
betes were significantly associated with
larger volumes of dWMHs (b 0.07 log-mL
[20.01 to 0.15] and 0.16 log-mL [0.08–
0.24], respectively; Ptrend ,0.001) and
pWMHs (b 0.06 log-mL [20.01 to 0.13]
and 0.20 log-mL [0.14–0.27], respec-
tively; Ptrend ,0.001). The regression
coefficients of prediabetes with WMH
volume were approximately one-third
to one-half that of the type 2 diabetes
coefficient, which suggests a continuous
association from NGM to prediabetes to
diabetes. No associations of prediabetes
or type 2 diabetes were found with the
presence of CMBs (OR 0.85 [95% CI
0.57–1.27] and 1.14 [0.80–1.62], respec-
tively; Ptrend = 0.567) (Table 2).
After full adjustment, prediabetes
and type 2 diabetes were significantly
associated with smaller white matter
volumes compared with NGM (b 24.0
mL [95% CI 27.3 to 20.6] and 27.2 mL
[210.4 to 24.0], respectively; Ptrend ,
0.001). The regression coefficient of
prediabetes with white matter volume
was approximately one-half that of the
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type 2 diabetes coefficient, which sug-
gests a continuous association from
NGM to prediabetes to diabetes. In ad-
dition, prediabetes and type 2 diabetes
were significantly associated with larger
CSF volumes compared with NGM (b
3.9 mL [0.8–7.6] and 12.5 mL [9.0–
16.1], respectively; Ptrend ,0.001). Pre-
diabetes was not associated with gray
matter volumes, while type 2 diabetes
was associated with lower gray matter
volumes, compared with NGM (b
20.4 mL [23.7 to 2.8] and 26.2 mL
[29.4 to 23.1], respectively; Ptrend ,
0.001) (Fig. 1 and Table 2).
Continuous Measures of
Hyperglycemia and Structural Brain
Abnormalities
After full adjustment, HbA1c, fasting plasma
glucose, and 2-h postload glucose levels
were associated with the presence
of LIs (OR 1.28 [95% CI 1.09–1.50], P =
0.002; 1.22 [1.03–1.44], P = 0.020; and
1.21 [1.01–1.44], P = 0.039, per SD, re-
spectively) (Table 3) and higher volumes
of WMHs, dWMHs, and pWMHs (stan-
dardized b for WMH 0.09 [95% CI 0.05–
0.13], P , 0.001; 0.11 [0.07–0.15], P ,
0.001; and 0.11 [0.07–0.15], P , 0.001,
respectively) (Table 3). In addition,
HbA1c, fasting plasma glucose, and 2-h
postload glucose levels were associated
with lower white matter and gray matter
and higher CSF volumes (standardized b
for white matter20.02 [20.04 to 0.00],
P = 0.032; 20.03 [20.05 to 20.01], P =
0.007; and20.04 [20.06 to20.02], P,
0.001; for gray matter 20.04 [20.06
to 20.02], P , 0.001; 20.04 [20.06
to 20.02], P = 0.001; and 20.02
[20.04 to 0.00], P = 0.035; and for
CSF 0.07 [0.05–0.10], P , 0.001; 0.08
[0.05–0.11], P , 0.001; and 0.07 [0.05–
0.10], P , 0.001, respectively). No asso-
ciations of HbA1c, fasting plasma glucose,
or 2-h postload glucose levels were found
with the presence of CMBs (OR 1.04
[95% CI 0.90–1.20], P = 0.580; 1.03
[0.89–1.19], P = 0.668; and 0.98 [0.84–
1.13], P = 0.743, per SD, respectively).
Scatterplots with regression lines of con-
tinuous measures of hyperglycemia with
WMH volume are provided in Supple-
mentary Fig. 2.
Additional Analyses
When we used volumes in percentage
of intracranial volume, instead of volumes
in milliliters and corrected for intracranial
volume, associations of prediabetes and
type 2 diabetes, HbA1c, fasting glucose,
and 2-h postload glucose with structural
Table 1—General characteristics of the study population
NGM (n = 1,373) Prediabetes (n = 347) Type 2 diabetes (n = 508) Ptrend
Demographics
Age (years) 57.6 6 8.1 61.1 6 7.6 62.5 6 7.5 ,0.001
Sex (% female) 55.6 44.5 31.1 ,0.001
Glucose metabolism
Fasting glucose (mmol/L) 5.2 6 0.4 5.9 6 0.6 7.4 6 1.2 ,0.001
2-h postload glucose (mmol/L)* 5.4 6 1.1 8.1 6 1.8 14.1 6 4.1 ,0.001
HbA1c (%) 5.4 6 0.3 5.7 6 0.4 6.6 6 0.6 ,0.001
HbA1c (mmol/mol) 36.1 6 3.7 38.6 6 4.4 48.1 6 7.0 ,0.001
Cardiovascular risk factors
BMI (kg/m2) 25.4 6 3.5 27.3 6 4.0 28.9 6 4.5 ,0.001
Systolic BP (mmHg) 130.7 6 16.8 136.2 6 16.3 139.5 6 16.3 ,0.001
Diastolic BP (mmHg) 75.3 6 9.9 77.5 6 9.6 77.8 6 9.4 ,0.001
Hypertension (%) 38.9 60.1 81.5 ,0.001
Total–to–HDL cholesterol ratio 3.6 6 1.2 3.9 6 1.2 3.7 6 1.2 ,0.001
Triglycerides (mmol/L) 1.2 6 0.7 1.6 6 1.0 1.7 6 0.9 ,0.001
eGFR (mL/min/1.73 m2) 90.5 6 13.0 87.0 6 13.7 85.8 6 16.3 ,0.001
History of CVD (%) 8.7 11.4 20.9 ,0.001
Medication use (%)
Antihypertension medication 20.5 39.6 69.9 ,0.001
Lipid-modifying medication 14.7 29.8 71.9 ,0.001
Lifestyle factors (%)
Smoking, never/former/current 40.9/47.8/11.3 30.1/59.5/11.3 32.5/54.7/12.8 0.001
Educational level, low/medium/high 25.2/28.3/46.5 32.7/30.9/36.4 41.3/30.1/28.5 ,0.001
Markers of cerebral small-vessel disease
LIs present (%)† 4.1 7.9 9.0 ,0.001
Total WMH (mL) 0.17 (0.05–0.52) 0.27 (0.07–1.12) 0.40 (0.15–1.31) ,0.001
dWMH (mL) 0.04 (0.01–0.15) 0.08 (0.01–0.30) 0.09 (0.02–0.40) ,0.001
pWMH (mL) 0.20 (0.05–0.73) 0.30 (0.09–0.90) 0.12 (0.04–0.37) ,0.001
CMBs present (%)‡ 10.9 12.3 15.8 0.020
Brain volumes (mL)
White matter 479.6 6 59.5 468.3 6 62.6 466.0 6 60.0 ,0.001
Gray matter 666.6 6 58.8 654.3 6 62.9 648.0 6 61.6 ,0.001
CSF 247.2 6 45.8 257.2 6 50.0 268.8 6 50.4 ,0.001
Intracranial 1,394.1 6 133.9 1,381.1 6 146.2 1,384.7 6 131.7 0.148
MRI lag time (years) 2.4 6 1.3 2.4 6 1.3 2.4 6 1.3 0.608
Data are presented as means 6 SD or median (interquartile range) unless otherwise indicated and are stratified for (pre)diabetes status: NGM,
prediabetes, or type 2 diabetes. BP, blood pressure; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate. *2-h postload glucose
values were available in n = 2,111. †Data on LIs were available in n = 2,190. ‡Data on CMBs were available in n = 2,149.
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brain abnormalities remained similar
(Supplementary Tables 2 and 3). When
we replaced office with 24-h ambulatory
systolic blood pressure in the models,
or added blood pressure–lowering and
lipid-modifying medication to the mod-
els, associations remained similar (Supple-
mentary Tables 4 and 5). Furthermore,
when we additionally adjusted for
eGFR ,60 mL/min/1.73 m2 and urinary
albumin excretion .30 mg/24 h, as-
sociations did not materially change
(Supplementary Tables 6 and 7). When
we used HbA1c to assess glucose metab-
olism status (NGM HbA1c ,5.7%, pre-
diabetes HbA1c 5.7–6.5%, and type 2
diabetes HbA1c $6.5%), associations
did not materially change (Supplemen-
tary Table 8). In addition, when we
excluded participants with evidence
of a brain infarct on MRI (n = 42 [data
not shown]) or participants with an
MRI lag time .1.0 years (n = 1,333)
(Supplementary Table 9), associations
remained similar. Finally, associations
among prediabetes, type 2 diabetes,
and measures of glycemia did not differ
significantly between men and women
(Pinteraction .0.10).
CONCLUSIONS
This study demonstrates that prediabe-
tes, as well as continuous measures of
hyperglycemia (HbA1c and fasting and
2-h postload plasma glucose levels), is
associated with structural brain abnor-
malities (cerebral small-vessel disease
and brain atrophy), independent of ma-
jor cardiovascular risk factors. To put
these results into perspective, the struc-
tural brain abnormalities observed were
comparable with 2.1 years of brain aging
in prediabetes and 5.9 years in type 2
diabetes. This study therefore provides
further evidence that prediabetes is
not a benign state (25,36) and stresses
that prediabetes provides an opportu-
nity for the prevention of brain diseases.
This large population-based study
shows that prediabetes and continuous
measures of hyperglycemia are associ-
ated with LIs, WMHs, and brain atrophy.
Thus, our findings are consistentwith the
concept that the associations between
glycemia and structural brain abnormal-
ities are of a continuous nature. In con-
trast to our findings, the ARIC-NCS study
recently reported no associations of
prediabetes with LIs, WMHs, CMBs, or
smaller brain volumes (23). This may
be explained by differences in study
population, since the ARIC-NCS study
population was ;16 years older com-
pared with our study population, while
there is evidence to suggest that the
effects of cardiovascular risk factors
(including hyperglycemia) on structural
brain abnormalities are most profound
in middle-aged individuals (24,37). In ad-
dition, the ARIC-NCS study determined
prediabetes status based on HbA1c levels
only, whereas we determined prediabe-
tes status based on both an OGTT and
HbA1c levels (Table 2 and Supplementary
Table 8). Previous studies reported a
higher prevalence of LIs and smaller
white and gray matter volumes in
type 2 diabetes (10) as well as (mostly
nonsignificant) associations of predia-
betes, HbA1c, and fasting plasma glu-
cose with brain volumes (15,38–48).
Table 2—Multivariable-adjusted differences in structural brain abnormalities among individuals with prediabetes and
individuals with type 2 diabetes, as compared to individuals with NGM
Prediabetes Type 2 diabetes Ptrend
Markers of cerebral small-vessel disease
LIs (yes/no), OR (95% CI)
Model 1 1.62 (1.00–2.64) 1.71 (1.11–2.63) 0.012
Model 2 1.61 (0.98–2.63) 1.67 (1.04–2.68) 0.027
Total WMH volume (log-mL), b (95% CI)
Model 1 0.08 (0.00–0.15) 0.22 (0.16–0.29) ,0.001
Model 2 0.07 (0.00–0.15) 0.21 (0.14–0.28) ,0.001
dWMH volume (log-mL), b (95% CI)
Model 1 0.08 (0.00–0.16) 0.17 (0.10–0.24) ,0.001
Model 2 0.07 (20.01–0.15) 0.16 (0.08–0.24) ,0.001
pWMH volume (log-mL), b (95% CI)
Model 1 0.07 (0.00–0.14) 0.22 (0.16–0.28) ,0.001
Model 2 0.06 (20.01–0.13) 0.20 (0.14–0.27) ,0.001
CMBs (yes/no), OR (95% CI)
Model 1 0.85 (0.57–1.26) 1.17 (0.85–1.26) 0.433
Model 2 0.85 (0.57–1.27) 1.14 (0.80–1.62) 0.567
Brain volumes
White matter volume (mL), b (95% CI)
Model 1 23.2 (26.5 to 0.1) 26.1 (29.0 to 23.1) ,0.001
Model 2 24.0 (27.3 to 20.6) 27.2 (210.4 to 24.0) ,0.001
Gray matter volume (mL), b (95% CI)
Model 1 21.1 (24.4 to 2.1) 28.2 (211.1 to 25.3) ,0.001
Model 2 20.4 (23.7 to 2.8) 26.2 (29.4 to 23.1) ,0.001
CSF (mL), b (95% CI)
Model 1 3.9 (0.3–7.6) 13.4 (10.1–16.7) ,0.001
Model 2 3.9 (0.8–7.6) 12.5 (9.0–16.1) ,0.001
Associations of prediabetes and type 2 diabetes with structural brain abnormalities in the study population. ORs with 95% CI represent the
risk of the presence of LIs or CMBs, and regression coefficients indicate the mean difference with 95% CI in total WMH, dWMH, and pWMH
volumes orwhitematter, graymatter, and CSF volumes of participants with prediabetes or type 2 diabetes comparedwithNGM.Model 1: adjusted for
age, sex, intracranial volume (only for analyses with WMH, white matter, gray matter, and CSF) and time between baseline and MRI measurements.
Model 2: model 1 adjustments with additional adjustment for BMI, smoking status, total–to–HDL cholesterol ratio, office systolic blood pressure,
estimated glomerular filtration rate, and educational level.
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Importantly, and in contrast to previous
studies (10,15,38–48), we used 3T MRI
with SWI and GRE sequences, which
increased sensitivity to detect structural
brain abnormalities compared with 1.5T
MRI without SWI (49,50). In addition, we
showed that our findings were indepen-
dent of a broad array of cardiovascu-
lar risk factors. We used linear trend
analyses to test for a graded increase
in structural brain abnormalities from
NGM to prediabetes to type 2 diabetes.
Indeed, the increase in structural brain
abnormalities in prediabetes was ap-
proximately one-third to one-half that
in type 2 diabetes (Table 3 and Fig. 1). In
addition, the interpretation of a graded
increase is supported by the significant
associations of continuous measures of
glycemia with structural brain abnormal-
ities. We attribute the lack of statistical
significance of the association between
prediabetes and gray matter volumes to
a type 2 statistical error because power in
between-group comparisons is reduced
compared with trend analyses. We
found no associations of prediabetes,
type 2 diabetes, or continuous measures
of hyperglycemia with CMBs, which is in
line with previous studies (51,52).
The associations of prediabetes and
continuous measures of hyperglycemia
with structural brain abnormalities can
be explained by several, not mutually
exclusive, mechanisms (53). First, hyper-
glycemia is associated with generalized,
including cerebral, microcirculatory en-
dothelial dysfunction (22), which in turn
may lead to cerebral perfusion deficits,
resulting in chronic ischemia of the brain
tissue (54,55). Chronic ischemia can in-
duce structural abnormalities in cere-
bral white matter, which are visualized
as WMHs on MRI (54–61). The brain is
particularly susceptible to such perfusion
deficits, as it has a high energy demand
but no reserve energy capacity. More-
over, the cerebral endothelium and
blood-brain barrier are vulnerable to
oxidative stress, which can occur as a
result of hyperglycemia-associated in-
creased production of reactive oxygen
species and limited antioxidant defenses
in the brain (62–65). Blood-brain barrier
disruption, in turn, can lead to vessel wall
thickening, disorganization and break-
down of the cerebral microcirculation,
and enlargement of perivascular spaces,
edema, and tissue damage, which can
contribute to structural brain abnor-
malities (65,66). Second, hyperglycemia
may directly induce neurodegeneration
(glucotoxicity) through the polyol, hexos-
amine, and advanced glycation end
product pathways; oxidative stress; and
inflammation (67–69). Third, cerebral
insulin resistance may impair regional
glucose metabolism and disrupt the
intracellular release, and extracellular
clearance, of b-amyloid and thus con-
tribute to neurodegeneration and brain
atrophy. In addition, cerebral microvas-
cular endothelial dysfunction and blood-
brain barrier disruption may reduce
insulin transport to brain parenchyma
and thus furtherenhancecerebral insulin
resistance (70,71).
Strengths of our study include its
population-based design with oversam-
pling of participantswith type 2diabetes,
which enabled an accurate comparison
of individuals with prediabetes com-
pared with individuals with type 2 di-
abetes; the use of 3T MRI, which has a
high sensitivity to detect WMHs (49),
and the use of SWI, which has a high
sensitivity to detect CMBs (50); the use
of fully automated brain segmentation
and WMH detection, which is the pre-
ferred technique for investigating brain
anatomy (72); the use of HbA1c levels
and an OGTT to accurately characterize
glucose metabolism; and the extensive
assessment of potential confounders.
Our study also has limitations. First, we
used cross-sectional data; therefore,
we cannot exclude reverse causality. In
view of previous research (10), it is likely
that hyperglycemia can cause structural
Figure 1—A: Mean volumes, adjusted for intracranial volume, of WMHs, white matter, and gray matter in individuals with NGM, individuals with
prediabetes, and individuals with type 2 diabetes (T2D). B: Fully adjusted differences in volumes in participants with prediabetes and participants with
type 2 diabetes compared with NGM. Data are presented as mean with 95% CI.
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brain abnormalities. However, the brain
can directly regulate the glucose metab-
olism (73–75). Structural brain abnor-
malities may disrupt, or be a marker
of disruption of, local signaling path-
ways, which may impair brain regulation
of glucose metabolism (76). Thus, the
associations we observed may be bi-
directional. Second, the time passed
between biochemical and MRI measure-
ments might have influenced the asso-
ciations observed; however, we adjusted
for this in all analyses, which, moreover,
did not significantly influence the results.
In addition, we performed additional
analyses in which participants with a
MRI lag time .1.0 year were excluded,
which did not substantially affect our
results. Third, our study population was
intensively treated with regard to car-
diovascular risk factors, was mainly of
Caucasian race, and was aged 40–75
years. This should be considered when
extrapolating our findings to other pop-
ulations. Fourth, although we adjusted
for major potential confounders, in-
cluding cardiovascular risk factors, we
cannot fully exclude the possibility of
residual confounding by variables not
included in these analyses.
In conclusion, we showed, in a general
population, that prediabetes and contin-
uous measures of hyperglycemia are
associated with structural brain abnor-
malities, independent of major cardio-
vascular risk factors. These findings
support the concept that cerebrovascu-
lar andneurodegenerative abnormalities
can already be observed in the predia-
betes phase, prior to the diagnosis of
type 2 diabetes, and contribute to the
cerebral complications of type 2 diabetes
and prediabetes, such as stroke, demen-
tia, and depression. Our study supports
the concept that treatment of predi-
abetes should be considered for the
prevention of complications of type 2
diabetes (77), including structural brain
abnormalities and brain disease.
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Table 3—Multivariable-adjusted associations of HbA1c, fasting glucose, and 2-h postload glucose levels with structural brain
abnormalities
HbA1c P Fasting glucose P 2-h postload glucose P
Markers of cerebral small-vessel
disease
LIs (yes/no), OR (95% CI)
Model 1 1.28 (1.11–1.49) 0.001 1.22 (1.05–1.42) 0.009 1.19 (1.00–1.40) 0.047
Model 2 1.28 (1.09–1.50) 0.002 1.22 (1.03–1.44) 0.020 1.21 (1.01–1.44) 0.039
Total WMH volume (log-mL),
b (95% CI)
Model 1 0.10 (0.07–0.14) ,0.001 0.12 (0.08–0.15) ,0.001 0.12 (0.08–0.15) ,0.001
Model 2 0.09 (0.05–0.13) ,0.001 0.11 (0.07–0.15) ,0.001 0.11 (0.07–0.15) ,0.001
dWMH volume (log-mL),
b (95% CI)
Model 1 0.07 (0.03–0.11) 0.001 0.09 (0.05–0.12) ,0.001 0.07 (0.03–0.11) ,0.001
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Associations between continuous measures of glycemia and structural brain abnormalities in the study population. ORs with 95% CI represent
the risk of the presence of LIs or CMBs, and standardized b and 95% CIs indicate the mean difference in WMH, dWMH, and pWMH
volumes or white matter, gray matter, and CSF volumes per SD increase in HbA1c, fasting plasma glucose, or 2-h postload glucose. Model 1:
adjustment for age, sex, intracranial volume, and time between baseline and MRI measurements. Model 2: model 1 adjustments plus
additional adjustment for BMI, smoking status, total–to–HDL cholesterol ratio, office systolic blood pressure, estimated glomerular filtration
rate, and educational level.
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77. Carlsson LMS, Sjöholm K, Karlsson C, et al.
Long-term incidence of microvascular disease
after bariatric surgery or usual care in patients
with obesity, stratified by baseline glycaemic
status: a post-hoc analysis of participants from
the Swedish Obese Subjects study. Lancet Dia-
betes Endocrinol 2017;5:271–279
care.diabetesjournals.org van Agtmaal and Associates 2543
